Literature DB >> 34992217

Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence.

Tongtong Kan1,2, Shupeng Zhang3, Shengtao Zhou4, Ya Zhang3, Yun Zhao5, Yinghua Gao3, Tao Zhang6, Feng Gao7, Xin Wang7, Linjie Zhao4, Mengsu Yang8,9.   

Abstract

Epithelial ovarian cancers (EOCs) are sensitive to chemotherapy but will ultimately relapse and develop drug resistance. The origin of EOC recurrence has been elusive due to intra-tumor heterogeneity. Here we performed single-cell RNA sequencing (scRNA-seq) in 13,369 cells from primary, untreated peritoneal metastasis, and relapse tumors. We used time-resolved analysis to chart the developmental sequence of cells from the metastatic tumors, then traced the earliest replanting cells back to the primary tumors. We discovered seven distinct subpopulations in primary tumors where the CYR61+ "stress" subpopulation was identified as the relapse-initiators. Furthermore, a subpopulation of RGS5+ cancer-associated fibroblasts (CAFs) was found to strongly support tumor metastasis. The combined CYR61/RGS5 expression scores significantly correlated with the relapse-free-survival of EOC patients and can be used as predictors of EOC recurrence. Our study provides insights into the mechanism of EOC recurrence and presents CYR61+ relapse-initiating cells as potential therapeutic targets to prevent EOC relapse.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 34992217     DOI: 10.1038/s41388-021-02139-z

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  47 in total

Review 1.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

Review 2.  Optimizing treatment in recurrent epithelial ovarian cancer.

Authors:  Giacomo Corrado; Vanda Salutari; Eleonora Palluzzi; Maria Grazia Distefano; Giovanni Scambia; Gabriella Ferrandina
Journal:  Expert Rev Anticancer Ther       Date:  2017-11-06       Impact factor: 4.512

3.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

4.  Cardiac output changes with altered acid-base status during methoxyflurane anaesthesia.

Authors:  W W Stoyka
Journal:  Can Anaesth Soc J       Date:  1972-03

5.  Ovarian cancer development and metastasis.

Authors:  Ernst Lengyel
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

Review 6.  Framework models of tumor dormancy from patient-derived observations.

Authors:  Christoph A Klein
Journal:  Curr Opin Genet Dev       Date:  2010-12-08       Impact factor: 5.578

Review 7.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

Review 8.  Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action.

Authors:  M Abal; J M Andreu; I Barasoain
Journal:  Curr Cancer Drug Targets       Date:  2003-06       Impact factor: 3.428

9.  Ovarian cancer.

Authors:  Bryan T Hennessy; Robert L Coleman; Maurie Markman
Journal:  Lancet       Date:  2009-09-28       Impact factor: 79.321

10.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245

View more
  3 in total

1.  Hexokinase 2 promoted cell motility and proliferation by activating Akt1/p-Akt1 in human ovarian cancer cells.

Authors:  Xueye Tian; Dan Liu; Xiaohang Zuo; Mengmin Wu; Xu Li; Yue Teng; Xiaoli Sun
Journal:  J Ovarian Res       Date:  2022-08-11       Impact factor: 5.506

2.  Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.

Authors:  Shruthi Sriramkumar; Tara X Metcalfe; Tim Lai; Xingyue Zong; Fang Fang; Heather M O'Hagan; Kenneth P Nephew
Journal:  PLoS One       Date:  2022-08-03       Impact factor: 3.752

Review 3.  Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations.

Authors:  Amy H Lee; Carolina Mejia Peña; Michelle R Dawson
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.